Register to leave comments

  • News bot April 3, 2026, 8:39 p.m.

    🔍 Patel Sanj K (Executive)

    Company: Kiniksa Pharmaceuticals International, plc (KNSA)

    Report Date: 2026-04-01

    Transaction Summary:

    • Total transactions: 10
    • Derivative instruments: 6
    • Holdings reported: 2
    • Total shares acquired: 231,627
    • Total shares sold: 31,640
    • Total shares held: 161,589

    Detailed Transactions and Holdings:

    • Acquired 21,327 shares of Class A Ordinary Share (Direct)
      Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 81,327.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 10,313 shares of Class A Ordinary Share at $48.13 per share (Direct)
      Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 71,014.00 | transaction_form_type: 4
    • Holds 0 shares of Class A Common Share (Direct)
      Date: 2026-04-01 | Code: H | nature_of_ownership: Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | shares_owned_after: 109,795.00
    • Holds 0 shares of Class A Ordinary Share (Direct)
      Date: 2026-04-01 | Code: H | nature_of_ownership: Held by The Anglia 2013 Revocable Trust | shares_owned_after: 51,794.00
    • Acquired 120,150 shares of Share Option at $48.13 per share (Derivative)
      Date: 2026-04-01 | Code: A | Expires: 2036-03-31 | equity_swap_involved: 0 | shares_owned_after: 120,150.00 | transaction_form_type: 4 | Footnotes: F2
    • Acquired 30,050 shares of Restricted Share Unit (Derivative)
      Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 30,050.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
    • Acquired 60,100 shares of Performance Share Unit (Derivative)
      Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 60,100.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
    • Sold 6,481 shares of Restricted Share Unit (Derivative)
      Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,481.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6
    • Sold 6,237 shares of Restricted Share Unit (Derivative)
      Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,475.00 | transaction_form_type: 4 | Footnotes: F1, F7, F7
    • Sold 8,609 shares of Restricted Share Unit (Derivative)
      Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 25,826.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8

    Footnotes:

    • F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
    • F2: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026.
    • F3: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter.
    • F4: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
    • F5: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply.
    • F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023.
    • F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024.
    • F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025.